Parkinson Atypical Rating of Oculometric Patterns Evaluated Routinely

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ENROLLING_BY_INVITATION

Clinical Phase

NA

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-09-10

Study Completion Date

2025-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is an observational longitudinal study in 4 cohorts of patients with Parkinsonian syndromes, who are visiting the Movement Disorders outpatient clinics.

The aim of the study is to assess the difference of oculometric measures in different neurodegenerative brain conditions and their accuracy over time, and as compared to clinical diagnosis, in order to find a change over time, difference between subgroups and correlations with accepted clinical endpoints in subjects who meet the inclusion criteria and who provide a signed Informed Consent.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Longitudinal Evaluation of Oculometric Measures and Clinical Assessment Over Time in PD Patients

NCT05795023

Parkinson Disease

COMPLETED NA

Evaluation of Correlation Between Oculometric Measures and Clinical Assessment in Parkinson's Disease

NCT05862649

Parkinson Disease

RECRUITING NA

" Visual Characterization of Parkinson's Patients and Oculomotor or Perceptual Therapy"

NCT06032130

Parkinson Disease

RECRUITING

A Prospective Study to Evaluate the Correlation Between Oculometric Measurements and Clinical Endpoints in PD Patients

NCT05437003

Idiopathic Parkinson Disease

COMPLETED NA

Study on the Visual Condition in Parkinson's Disease

NCT03743467

Parkinson Disease

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

As a part of the study, about 40 subjects will undergo a neurological evaluation including motor and cognitive assessments and a NeuraLight session including oculometric measurements and eye-tracking recordings using a novel software-based platform and an eye-tracking system (Tobii, CE-marked class B approved device). Test duration will be approx. 20 minutes. The oculometric evaluation will occur for at least 50% of the cohort 3 times (at baseline, at 6-months and at 12-month follow-up), and all subjects will be recruited over a period of 9 months. All assessments will be performed during a clinic visit unless authorized to be conducted remotely.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson Disease Progressive Supranuclear Palsy(PSP) Multiple System Atrophy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Parkinson patients

Patients diagnosed with Parkinson's disease, ages 50-80, Hoehn \& Yahr scale 1-3

Group Type ACTIVE_COMPARATOR

NeuraLight PD

Intervention Type OTHER

NeuraLight software-based platform for PD patients

PSP patients

Patients diagnosed with PSP, according to actual diagnostic criteria from Höglinger GU et al, 2017.

Group Type ACTIVE_COMPARATOR

NeuraLight PSP

Intervention Type OTHER

NeuraLight software-based platform for PSP patients

MSA patients

Patients diagnosed with MSA, according to actual diagnostic criteria from Wenning et al, 2022.

Group Type ACTIVE_COMPARATOR

NeuraLight MSA

Intervention Type OTHER

NeuraLight software-based platform for MSA patients

Healthy

Healthy subjects with no neurological diseases or cognition deficits

Group Type ACTIVE_COMPARATOR

NeuraLight

Intervention Type OTHER

NeuraLight software-based platform

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

NeuraLight PD

NeuraLight software-based platform for PD patients

Intervention Type OTHER

NeuraLight PSP

NeuraLight software-based platform for PSP patients

Intervention Type OTHER

NeuraLight MSA

NeuraLight software-based platform for MSA patients

Intervention Type OTHER

NeuraLight

NeuraLight software-based platform

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Men and women, age between 40 and 80 years
* \<5 years since disease diagnosis
* Normal or corrected vision
* MOCA score ≥ 20
* Ability to follow instructions
* Willing and able to sign an informed consent form Specific
* PD cohort: Ages 50-80, Hoehn \& Yahr scale 1-3
* PSP cohort: diagnosed according to actual diagnostic criteria from Höglinger GU et al, 2017.
* MSA cohort: diagnosed according to actual diagnostic criteria from Wenning et al, 2022.